Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression.

PubWeight™: 1.33‹?› | Rank: Top 10%

🔗 View Article (PMC 1234382)

Published in Ann Surg on September 01, 1994

Authors

S Todo1, J J Fung, T E Starzl, A Tzakis, H Doyle, K Abu-Elmagd, A Jain, R Selby, O Bronsther, W Marsh

Author Affiliations

1: Pittsburgh Transplant Institute, University of Pittsburgh Medical Center, Pennsylvania.

Articles citing this

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

Hepatic Retransplantation--an analysis of risk factors associated with outcome. Transplantation (1996) 1.22

Tacrolimus in pediatric renal transplantation. Transplantation (1996) 1.18

A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc (1995) 1.13

What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg (1999) 1.02

Acquired immunologic tolerance: with particular reference to transplantation. Immunol Res (2007) 0.97

Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg (1996) 0.95

Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation (2000) 0.92

A comprehensive review of immunosuppression used for liver transplantation. J Transplant (2009) 0.86

FK506 in solid organ transplantation. Ther Drug Monit (1995) 0.85

The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. Clin Transpl (1995) 0.85

Renal dysfunction associated with liver transplantation. Postgrad Med J (1995) 0.83

The future of transplantation: with particular reference to chimerism and xenotransplantation. Transplant Proc (1997) 0.83

Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg (1999) 0.81

Renal transplantation at the University of Pittsburgh: the impact of FK506. Clin Transpl (1994) 0.78

Science, specialization, and the American Surgical Association. Ann Surg (1997) 0.78

Hepatic and intestinal transplantation at the University of Pittsburgh. Clin Transpl (1998) 0.78

Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. Clin Transpl (1994) 0.76

The basis of allograft acceptance. Forum (Genova) (1997) 0.75

Advances in the development of immunosuppressive agents in organ transplantation. Surg Today (1997) 0.75

Articles cited by this

Evolution of liver transplantation. Hepatology (1982) 19.54

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet (1979) 12.29

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc (1987) 12.04

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc (1987) 8.45

THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. Surg Gynecol Obstet (1963) 8.04

The mechanism of action of cyclosporin A and FK506. Immunol Today (1992) 7.57

Kidney transplantation under FK 506. JAMA (1990) 7.45

A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature (1989) 7.02

Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95

Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science (1991) 6.80

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature (1989) 5.53

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol (1989) 4.30

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol (1992) 3.20

Renal transplantation in baboons under FK 506. Surgery (1989) 3.17

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506. Transplant Proc (1987) 2.84

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26

Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation (1987) 2.15

Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. Transplantation (1989) 2.03

Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. Lancet (1989) 2.01

The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83

Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72

Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. Transplantation (1992) 1.68

Hepatic artery thrombosis after pediatric liver transplantation--a medical or surgical event? Transplantation (1989) 1.67

Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation (1987) 1.65

Leukocyte chemotactic activity of cyclophilin. J Biol Chem (1992) 1.63

An immunophilin that binds M(r) 90,000 heat shock protein: main structural features of a mammalian p59 protein. Proc Natl Acad Sci U S A (1992) 1.56

Kidney transplantation in the dog receiving FK-506. Transplant Proc (1987) 1.54

Transplantation. JAMA (1989) 1.11

Heterotopic heart transplantation in the rat receiving FK-506. Transplant Proc (1987) 1.10

Immunophilin-ligand complexes as probes of intracellular signaling pathways. Transplant Proc (1991) 1.05

Histopathologic studies in renal transplant recipient dogs receiving treatment with FK-506. Transplant Proc (1987) 0.94

Portal and arterial thrombosis in liver transplantation: a frequent event in severe rejection. Transplant Proc (1989) 0.92

FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. Transplantation (1988) 0.88

Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. Transplantation (1989) 0.83

Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. Transplant Proc (1993) 0.81

Articles by these authors

Evolution of liver transplantation. Hepatology (1982) 19.54

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Racial discrimination in the allocation of distinction awards? Analysis of list of award holders by type of award, specialty and region. BMJ (1998) 12.93

A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11

Kidney transplantation under FK 506. JAMA (1990) 7.45

The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40

The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24

Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19

Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04

Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64

Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53

Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44

Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24

Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12

Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08

Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08

Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01

Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99

Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91

The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84

Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66

Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Hepatic Retransplantation. Transplant Proc (1985) 3.62

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49

Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49

Long-term survival after renal transplantation in humans: (with special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG , AND RECIPIENT MALIGNANCY). Ann Surg (1970) 3.48

Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med (1992) 3.42

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38

The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Characterization and localization of the even-skipped protein of Drosophila. EMBO J (1987) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Changes in blood coagulation. Arch Surg (1966) 3.22

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18